Your browser doesn't support javascript.
loading
Clinical and Radiologic Outcomes in Adults and Children Treated with Pencil-Beam Scanning Proton Therapy for Low-Grade Glioma.
Badiyan, Shahed N; Ulmer, Stephan; Ahlhelm, Frank J; Fredh, Anna S M; Kliebsch, Ulrike; Calaminus, Gabriele; Bolsi, Alessandra; Albertini, Francesca; Leiser, Dominic; Timmermann, Beate; Malyapa, Robert S; Schneider, Ralf; Lomax, Antony J; Weber, Damien C.
Afiliación
  • Badiyan SN; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Ulmer S; Medical Radiological Institute, Zurich, Switzerland.
  • Ahlhelm FJ; Department of Radiology, Cantonal Hospital Baden, Baden, Switzerland.
  • Fredh ASM; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Kliebsch U; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Calaminus G; Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
  • Bolsi A; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Albertini F; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Leiser D; University Hospital Inselspital, Bern, Switzerland.
  • Timmermann B; Clinic for Particle Therapy, West German Proton Center, University Hospital Essen, Germany.
  • Malyapa RS; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Schneider R; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Lomax AJ; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Weber DC; Department of Physics, Swiss Institute of Technology, Zurich, Switzerland.
Int J Part Ther ; 3(4): 450-460, 2017.
Article en En | MEDLINE | ID: mdl-31772995
PURPOSE: We assessed clinical and radiologic outcomes in adults and children with low-grade glioma (LGG) of the brain treated with pencil-beam scanning (PBS) proton therapy (PT). MATERIALS AND METHODS: Between 1997 and 2014, 28 patients were treated with PBS PT, 20 (71%) of whom were younger than 18 years. Median age at start of PT was 12.3 years (range, 2.2-53.0 years). Nine patients (32%) underwent at least a subtotal resection; 12 (43%) underwent biopsy; and 7 (25%) were diagnosed radiographically. Twelve patients (43%) had grade II and 9 (32%) had grade I gliomas. Eleven patients (39%) received chemotherapy before PT. A median dose of 54 Gy (relative biologic effectiveness) was administered. Radiologic response to PT was determined using the Response Evaluation Criteria in Solid Tumors (RECIST). Eight domains of quality of life (QoL) for 16 pediatric patients were assessed prospectively by patients' parents using the pediatric QoL proxy questionnaire. Progression-free survival and overall survival (OS) were estimated by the Kaplan-Meier method. Median follow-up was 42.1 months for living patients. RESULTS: Ten patients (36%) developed local, clinical failure. Three patients (11%) died, all of tumor progression. Radiographic tumor response by RECIST was evaluable in 11 patients: 9 (82%) with stable disease, 1 (9%) with partial response, and 1 (9%) with complete response to PT. Three-year OS and progression-free survival were 83.4% and 56.0%, respectively. No ≥ grade III acute toxicities were observed. Grade III, late radiation necrosis developed in 1 patient (4%). No appreciable change in pediatric QoL proxy scores in children was noted in any of the 8 domains at any time point. CONCLUSION: Treatment with PBS PT is effective for LGG, with minimal acute toxicity and, in children, no appreciable decline in QoL. More patients and longer follow-up are needed to determine the long-term efficacy and toxicity of PT for LGG.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Int J Part Ther Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Int J Part Ther Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos